Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc. (SDGR), sold 25,101 shares at $25.11 ($630K) on 2025-04-14, disclosed to the SEC on 2025-04-15.
Scheduled sale ($630k) by President of R&D, Therapeutics under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 3,345 | $84K | 13.3% |
| 2 | $25.11 | 5,000 | $126K | 19.9% |
| 3 | $25.11 | 8,378 | $210K | 33.4% |
| 4 | $25.11 | 8,378 | $210K | 33.4% |
| Total | $25.10 avg | 25,101 | $630K | 100% |
| Filing → |
| SDGR | SELL | 2026-03-03 | $53K | — | Filing → |
| SDGR | SELL | 2021-10-19 | $155K | — | Filing → |
| SDGR | SELL | 2021-09-16 | $170K | — | Filing → |